For forty years, the federal government maintained a paradoxical position on cannabis science: it classified cannabis as a Schedule I substance — meaning it had “no currently accepted medical use” — while simultaneously making it nearly impossible for researchers to study whether it had medical uses. The result was a self-reinforcing cycle of ignorance. Cannabis remained in the most restrictive scheduling category because there was insufficient evidence of therapeutic value, and there was insufficient evidence of therapeutic value because the scheduling made it nearly impossible to conduct the research that would generate that evidence.
That cycle is finally breaking. In fiscal year 2026, the National Institutes of Health allocated $300 million to cannabinoid research, an all-time high that represents a 500% increase from the $50 million allocated in 2015. The number marks a dramatic acceleration that began in earnest after the 2024 NIDA reauthorization and gained further momentum from the rescheduling of cannabis from Schedule I to Schedule III in late 2024. More researchers at more institutions are studying more aspects of cannabis than at any point in history.
But the number comes with a significant asterisk. Approximately 60% of that $300 million is still directed toward studying the harms and risks of cannabis use — addiction potential, cognitive effects, driving impairment, adolescent brain development — rather than its therapeutic potential. The bias toward harm research, baked into the institutional DNA of the agencies that control the funding, persists even as the political and cultural landscape has shifted decisively in the opposite direction.
The Funding Trajectory: 2010 to 2026
Tracking federal cannabis research funding over the past fifteen years reveals a story of slow acceleration followed by a sudden surge.
In 2010, the NIH spent approximately $30 million on cannabinoid research. Most of that money flowed through the National Institute on Drug Abuse (NIDA), whose mission — studying substance use disorders — naturally oriented its cannabis research portfolio toward harm, addiction, and abuse potential. A small number of grants addressed therapeutic applications, primarily through the National Cancer Institute (NCI) and the National Institute of Neurological Disorders and Stroke (NINDS), but these were modest relative to the NIDA portfolio.
Funding grew slowly through the early 2010s, reaching approximately $50 million by 2015. The growth was driven partly by increased interest in the endocannabinoid system as a basic science research area and partly by growing political pressure from states that had legalized medical cannabis without the federal research infrastructure to support evidence-based medical practice.
The 2018 Farm Bill, which legalized hemp and hemp-derived cannabinoids, created a new research category. CBD research in particular attracted increased NIH attention, with grants supporting studies of CBD for epilepsy, anxiety, pain, and inflammation. By 2020, total NIH cannabinoid research funding had reached approximately $150 million, triple the 2015 level.
The real inflection point came in 2024. Two developments converged: the NIDA reauthorization, which expanded the institute’s mandate to include therapeutic cannabis research alongside its traditional harm-focused portfolio, and the rescheduling of cannabis to Schedule III, which fundamentally changed the regulatory landscape for clinical research. Funding jumped to $225 million in FY2025 and reached $300 million in FY2026.
Where the Money Goes
The $300 million in FY2026 cannabinoid research funding is distributed across multiple NIH institutes, each with its own priorities and biases.
NIDA (National Institute on Drug Abuse): approximately $180 million. NIDA remains the largest funder of cannabinoid research by a wide margin. Historically, its cannabis portfolio was overwhelmingly focused on harm: addiction neuroscience, cannabis use disorder epidemiology, gateway drug hypothesis testing, adolescent brain development, and impaired driving. The 2024 reauthorization expanded NIDA’s mandate to include therapeutic cannabinoid research, and the institute has begun funding studies of cannabis for pain management, PTSD, and opioid use disorder substitution. However, the institutional culture and review panels still skew heavily toward harm research. By internal estimates, approximately 70% of NIDA’s cannabis portfolio still addresses harm and risk rather than therapeutic potential.
NCI (National Cancer Institute): approximately $35 million. NCI funds research on cannabinoids for cancer-related symptoms (nausea, pain, appetite loss), the anti-tumor properties of specific cannabinoids, and the interactions between cannabis use and cancer treatment outcomes. This is one of the more therapeutically oriented portfolios, with most grants focused on potential benefits rather than harms.
NINDS (National Institute of Neurological Disorders and Stroke): approximately $25 million. NINDS funds research on cannabinoids for epilepsy (building on the success of Epidiolex), multiple sclerosis, traumatic brain injury, and neurodegenerative diseases. The epilepsy research is the most mature, with multiple clinical trials funded or co-funded by NINDS.
NIMH (National Institute of Mental Health): approximately $20 million. NIMH funds research on cannabis and mental health, including studies of CBD for anxiety and PTSD, the relationship between cannabis use and psychosis, and the endocannabinoid system’s role in mood regulation. This portfolio is genuinely split between harm research (psychosis, schizophrenia risk) and therapeutic research (anxiety, PTSD, depression).
NCCIH (National Center for Complementary and Integrative Health): approximately $15 million. NCCIH, which funds research on complementary health approaches, has emerged as a significant funder of therapeutic cannabis research. Its grants tend toward whole-plant studies, terpene research, and investigations of the entourage effect — areas that other NIH institutes have been reluctant to fund.
Other NIH Institutes: approximately $25 million. Smaller allocations come from the National Institute on Aging (cannabis for age-related conditions), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (cannabis for chronic pain and inflammation), and several other institutes.
The Harm Research Bias
The disproportionate allocation of funding toward harm research is the most contentious issue in the federal cannabis research landscape. By NIH’s own categorization, approximately $180 million of the $300 million FY2026 allocation (60%) funds studies that primarily investigate the risks, harms, and negative consequences of cannabis use. Only about $90 million (30%) is directed toward therapeutic applications. The remaining $30 million (10%) funds basic science research on the endocannabinoid system that does not have a direct harm or therapeutic orientation.
This distribution reflects institutional history rather than scientific or public health priorities. NIDA was created in 1974 specifically to study drug abuse, and cannabis fell squarely within its portfolio. For decades, NIDA was essentially the only NIH institute funding cannabis research at scale, and its harm-focused mandate shaped the entire field. Researchers who wanted to study cannabis therapeutics learned to frame their grant applications in terms that aligned with NIDA’s mission — studying “cannabis use disorder” rather than “cannabis as medicine” — even when their underlying interest was therapeutic.
The review panels that evaluate cannabis research proposals remain heavily populated by researchers whose careers were built studying cannabis harms. These reviewers tend to score harm-focused applications more favorably, not out of malice but because their expertise and professional networks orient them toward those questions. Young researchers seeking to study therapeutic applications report that their grants receive skeptical reviews and lower priority scores compared to comparably designed studies focused on harm.
The rescheduling to Schedule III has created formal space for therapeutic research, but institutional change moves slowly. NIDA’s leadership has publicly committed to expanding its therapeutic portfolio, and the institute’s most recent strategic plan includes explicit goals for funding cannabis therapeutics. But the gap between stated priorities and funding allocation remains wide.
The Schedule III Effect
The reclassification of cannabis from Schedule I to Schedule III in late 2024 has transformed the practical landscape for cannabis researchers, even though its full effects are still unfolding.
Under Schedule I, researchers who wanted to study cannabis in human subjects faced extraordinary regulatory hurdles. They needed a Schedule I research license from the DEA, a separate registration for each research protocol, a designated Schedule I research site with specific security requirements, and — until 2021 — they were required to use cannabis supplied exclusively by the University of Mississippi’s NIDA-contracted growing facility, which was widely regarded as low-quality and unrepresentative of the products actually being used by consumers and patients.
Schedule III dramatically simplifies this process. Researchers still need DEA registration, but the requirements are substantially less burdensome. Schedule III research does not require the same level of physical security infrastructure. Most importantly, researchers can now legally obtain cannabis products from a wider range of sources, including state-licensed producers, for their studies. This means clinical trials can actually use the types of cannabis products that patients are consuming in the real world — a basic methodological requirement that was essentially impossible under Schedule I.
The impact on research capacity has been immediate. The number of active Investigational New Drug (IND) applications for cannabis-based therapies filed with the FDA increased by approximately 40% between 2024 and 2026. University institutional review boards (IRBs), which had historically been reluctant to approve cannabis studies due to the Schedule I complications, are now processing cannabis research protocols with the same efficiency as other Schedule III substances.
The pipeline of clinical trials has expanded correspondingly. As of early 2026, ClinicalTrials.gov lists over 400 active or recruiting clinical trials involving cannabis or cannabinoids, up from approximately 250 in 2023. The trials span a wide range of conditions: chronic pain, epilepsy, PTSD, anxiety, cancer-related symptoms, inflammatory bowel disease, autism spectrum disorder, opioid use disorder, and insomnia, among others.
New Research Categories
The expansion of federal funding has enabled research in categories that were previously starved for support.
Whole-plant research and the entourage effect: For years, the only federally funded cannabis research used purified single compounds — THC, CBD, or synthetic analogs. Research on the therapeutic effects of whole-plant cannabis, which contains hundreds of cannabinoids, terpenes, and flavonoids that may interact synergistically, was essentially unfundable. The entourage effect — the hypothesis that these compounds work better together than in isolation — was widely discussed but rarely studied rigorously. NCCIH and NIDA have both begun funding whole-plant studies, acknowledging that the compounds patients actually use are not isolated molecules.
Terpene therapeutics: Terpenes, the aromatic compounds responsible for cannabis’s distinctive flavors and aromas, have been understudied relative to their potential importance. Emerging research suggests that specific terpenes — linalool, beta-caryophyllene, limonene, myrcene — have independent pharmacological effects and may modulate how cannabinoids interact with receptor systems. New NIH grants are specifically investigating terpene-cannabinoid interactions.
Dosing and formulation science: One of the most significant gaps in cannabis medicine is the lack of standardized dosing guidelines. Unlike pharmaceutical drugs with precise milligram doses established through clinical trials, cannabis products are used at highly variable doses, with highly variable bioavailability depending on the consumption method. A new category of NIH-funded research is focused specifically on pharmacokinetics and pharmacodynamics of different cannabis formulations and delivery methods — the basic science necessary for rational dosing.
Cannabis and the microbiome: The endocannabinoid system is increasingly recognized as a regulator of gut function and the gut microbiome. New research grants are investigating the bidirectional relationship between cannabis consumption and microbiome composition, with implications for inflammatory bowel disease, metabolic disorders, and potentially mental health conditions through the gut-brain axis.
Geriatric cannabis research: The fastest-growing demographic of cannabis users is adults over 65, yet virtually no clinical research has been conducted on cannabis use in older adults. New NIH grants through the National Institute on Aging are beginning to address this gap, studying cannabis for age-related chronic pain, sleep disorders, and neurodegenerative conditions, while also investigating potential risks including drug interactions with common medications prescribed to older adults.
The MAPS Model: Lessons from Psychedelic Research
The cannabis research community is increasingly looking to the Multidisciplinary Association for Psychedelic Studies (MAPS) as a model for how to advance therapeutics through the federal research system. MAPS, a nonprofit founded in 1986, spent three decades navigating the same regulatory obstacles that cannabis researchers face, ultimately shepherding MDMA-assisted therapy through FDA-approved clinical trials and toward potential approval.
The MAPS model offers several lessons. First, nonprofit-funded research can complement and catalyze federal funding. MAPS invested its own funds in early-stage research that proved the concept, then used those results to attract NIH and FDA attention. Cannabis research organizations, including the newly expanded Realm of Caring Foundation and the Scotts Miracle-Gro-funded cannabis research endowments at several universities, are following a similar playbook.
Second, MAPS demonstrated that regulatory obstacles, however burdensome, are navigable with persistence and strategic engagement. The organization maintained constructive relationships with the FDA and DEA even while challenging their policies. Cannabis researchers who adopt a similar approach — working within the system while advocating for change — tend to be more successful than those who adopt an adversarial posture.
Third, MAPS showed that rigorous clinical data is ultimately what changes policy. Anecdotal evidence and patient testimonials, while compelling, did not move the regulatory needle. Phase 2 and Phase 3 clinical trial data did. The cannabis research community is increasingly focused on generating this caliber of evidence, recognizing that the path to federal policy change runs through published, peer-reviewed clinical data.
University Programs Expanding
The increase in federal funding has catalyzed a significant expansion of university-based cannabis research programs. As recently as 2018, only a handful of universities had formal cannabis research centers. Today, more than 40 universities have established dedicated cannabis research programs, centers, or institutes.
The University of Mississippi, which for decades held the sole federal contract to grow research cannabis, is no longer the only game in town. The DEA has licensed multiple new cannabis growers for research purposes, and the Schedule III reclassification has further expanded access. Universities can now more easily obtain research-grade cannabis that actually resembles the products patients use.
Notable programs include the Center for Medicinal Cannabis Research at UC San Diego, which has been a pioneer in clinical trials; the Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University; the University of Colorado’s expanding cannabinoid research portfolio; and newer programs at Johns Hopkins, NYU, and the University of Michigan. Harvard Medical School launched a cannabis research initiative in 2025, lending significant institutional credibility to the field.
These university programs are critical not only for the research they produce but for the training pipeline they create. The cannabis research field has long suffered from a talent shortage — there simply were not enough trained researchers with expertise in cannabinoid pharmacology, clinical trial design for cannabis, and the unique regulatory landscape of cannabis research. The proliferation of university programs is beginning to address this gap, producing a new generation of researchers for whom cannabis science is a viable and respected career path.
The Researcher Pipeline Problem
Despite the growth in funding and institutional infrastructure, the cannabis research field faces a significant human capital challenge. Decades of federal hostility toward cannabis research created a chilling effect on academic careers. Promising scientists were warned away from cannabis research by mentors who viewed it as career-ending. Grant review panels were stacked with skeptics. Publishing cannabis research in high-impact journals was difficult. The result is a field that has fewer senior researchers, fewer trained clinical investigators, and fewer established research networks than its funding level would otherwise support.
The pipeline problem manifests in several ways. Grant applications for cannabis research, particularly therapeutic research, are frequently reviewed by panels that lack deep expertise in cannabinoid pharmacology. The reviewers are competent scientists but may not appreciate the nuances of cannabis-specific study design challenges — issues like blinding (cannabis’s distinctive smell and psychoactive effects make true blinding difficult), standardization (whole-plant products vary between batches), and the complex pharmacology of multi-compound preparations.
Training programs are expanding, but it takes years to develop independent investigators. A graduate student who begins a PhD in cannabinoid neuroscience in 2026 will not be leading independent research programs until the mid-2030s. In the interim, the field relies on established researchers from adjacent areas — pain research, neuroscience, pharmacology, addiction science — who pivot into cannabis research. These pivots bring valuable methodological expertise but often lack the deep domain knowledge that comes from years of focused study.
The salary competition with the private cannabis industry adds another dimension. Researchers with expertise in cannabis science are highly sought by cannabis companies for product development, regulatory affairs, and clinical research positions. The private sector can offer significantly higher compensation than academic positions, creating a talent drain that further constrains the research pipeline.
Key Studies Currently Underway
Several large-scale, federally funded cannabis studies currently in progress have the potential to significantly advance the evidence base.
A multi-site clinical trial coordinated by the University of California system is studying whole-plant cannabis for chronic noncancer pain, comparing standardized cannabis preparations to placebo in a randomized controlled design. This trial, with over 500 planned participants, is the largest of its kind and could provide the type of definitive efficacy data that has been lacking.
NIDA is funding a longitudinal study tracking cognitive outcomes in a cohort of 3,000 adults who initiated regular cannabis use after age 21, comparing them to matched non-using controls over a ten-year period. This study aims to definitively address the question of whether adult-onset cannabis use causes lasting cognitive changes — a question that existing cross-sectional and short-term studies have been unable to resolve.
The VA has expanded its cannabinoid research program to include a multi-site trial of CBD for PTSD in veterans, building on promising pilot data. This trial is significant both for its potential clinical impact and for the symbolism of the Veterans Administration actively studying cannabis therapeutics.
Johns Hopkins is leading a study on psilocybin-cannabis interactions for treatment-resistant depression, funded through NIMH. This study represents a new frontier in which cannabis compounds are studied not in isolation but in combination with other emerging therapeutics.
A consortium of universities is conducting the first large-scale pharmacokinetic study of commercially available cannabis products, measuring blood levels of THC, CBD, and major terpenes across different formulations, delivery methods, and dosing regimens. The results will provide the basic pharmacological data needed to develop rational dosing guidelines — information that, remarkably, does not currently exist for most cannabis products.
Comparing Cannabis to Other Research Budgets
Placing the $300 million cannabis research budget in context with other federal research investments illuminates both how far cannabis research has come and how far it has to go.
The NIH’s total budget for FY2026 exceeds $48 billion. Cannabis research at $300 million represents about 0.6% of that total. By comparison, cancer research receives approximately $7.5 billion (15.6%), HIV/AIDS research receives approximately $3.4 billion (7.1%), and diabetes research receives approximately $1.2 billion (2.5%). Even alcohol research, through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), receives approximately $560 million — nearly double the cannabis research budget — despite cannabis being used by a comparable number of Americans.
The comparison to private-sector pharmaceutical research is even more stark. A single large pharmaceutical company may spend $10-15 billion annually on research and development. The entire federal cannabis research budget represents what a major pharma company might spend on a single promising drug candidate through the clinical trial process.
These comparisons are not meant to suggest that cannabis research deserves $7 billion. They are meant to illustrate that $300 million, while a record high for cannabis, is still a modest investment relative to the scale of cannabis use in America (approximately 55 million regular users), the breadth of potential therapeutic applications, and the fundamental gaps in basic knowledge about how cannabis affects the human body.
The Road Ahead
The $300 million milestone is significant not as an endpoint but as an inflection point. The trajectory of cannabis research funding is upward, the institutional barriers are diminishing, and the political environment is more supportive than at any point in history.
But the structural challenges remain formidable. The harm research bias, while slowly shifting, will take years to fully rebalance. The researcher pipeline will take a decade to fully mature. The regulatory infrastructure, while vastly improved, still imposes meaningful friction on clinical research.
The most important variable may be what the research produces. If the clinical trials currently underway generate strong efficacy data for cannabis therapeutics — particularly for conditions where existing treatments are inadequate, like chronic pain, PTSD, and treatment-resistant epilepsy — the political and institutional support for expanded research funding will accelerate. Negative or ambiguous results could slow the momentum.
What is no longer in question is whether the federal government will fund cannabis research at meaningful levels. That debate is over. The question now is whether the research infrastructure can deploy these resources effectively enough to produce the evidence that patients, clinicians, and policymakers need to make informed decisions about cannabis medicine.
After decades of deliberately looking away, the federal research establishment is finally looking at cannabis. What it sees will shape policy for the next generation.